January 2014

Bundled payments, big data, and advances in personalized medicine will change the way primary care physicians and others practice

Provider groups put money into systems that heighten the focus on measuring performance

Qsymia and Belviq can slow the progression of diabetes, but side effects and retail cost of about $200 per month are obstacles to formulary placement

Emerging data show impressive results on glycemic control, but what about long-term results, safety, and high maintenance costs?



Consumers expect reasonable premiums and copayments but give health plans grief over a proven cost-control method. How soon we forget.


Management tactic borrowed from traditional pharmacy


Twenty-five years ago we had not even identified the virus that was neither type A nor type B. Now we have slowed its spread and can cure it, at considerable cost.